Clinical Trials Logo

Clinical Trial Summary

* single center, prospective study First, evaluate the lesion under the white light endoscopy (WLE) → IV fluorescein sodium 0.1mL/kg → evaluate the lesion under probe-based confocal laser microendoscopy → target biopsy under the pCLE → random biopsy under WLE


Clinical Trial Description

The purpose of this study is to conduct a study on genetic pathology, obtaining of cancer tissues is mandatory. Although the endoscopy with biopsy has been a gold standard for diagnosing gastric cancer, percentage of cancer cells in biopsy samples of patients after chemotherapy is usually 30% or less. Because cancer cells are often replaced with regenerative cells after chemotherapy, even though there are still remnant cancer cells in the stomach. Recently, confocal laser endomicroscopy has been introduced for real-time histopathologic diagnosis in various cancers. In previous pilot study in our institution, pCLE-targeted biopsy provided superior results in terms of the proportion of cancer cells in biopsy samples compared to WLE-targeted biopsy, especially for gastric cancers with undifferentiated histology. However, there was no previous study about precious biopsy method for patients after chemotherapy. Therefore, the investigators aim to evaluate that biopsy using probe-based confocal laser endomicroscopy for remnant gastric cancer after chemotherapy will increase the percentage of cancer cells and expression ratio of tumor marker in biopsy samples. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03449966
Study type Interventional
Source Yonsei University
Contact Sang Kil Lee, MD
Phone 82-2-2228-1996
Email sklee@yuhs.ac
Status Recruiting
Phase N/A
Start date February 20, 2018
Completion date October 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Completed NCT00821990 - Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer Phase 3
Recruiting NCT04385641 - Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer N/A
Completed NCT01248403 - A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy Phase 3
Not yet recruiting NCT01206218 - Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer Phase 2/Phase 3
Completed NCT01851941 - A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer Phase 2
Completed NCT00976768 - Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin Phase 2
Active, not recruiting NCT03223376 - A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) Phase 3
Completed NCT03609359 - Lenvatinib and Pembrolizumab Simultaneous Combination Study Phase 2
Completed NCT03350477 - Bioinformation Therapy for Gastric Cancer Phase 2/Phase 3
Completed NCT02935634 - A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer Phase 2
Active, not recruiting NCT03579784 - Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer Phase 2
Completed NCT02952729 - Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Phase 1
Recruiting NCT02072317 - Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer Phase 2
Terminated NCT01402401 - Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients Phase 2
Completed NCT01503372 - FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer Phase 2
Completed NCT01472250 - A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China N/A
Recruiting NCT01015339 - Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Phase 3
Completed NCT00842491 - Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer Phase 2
Completed NCT02071043 - Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis Phase 2